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Abstract
Purpose
Metabolic changes induced by radiation therapy (RT) provide a bio-
logical measure of tumor response to treatment beyond anatomic
changes. In this preclinical study we investigated these changes through
longitudinal monitoring of tumor response to varying doses of RT with
18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
and Computed Tomography (CT), as well as bioluminescence imaging
(BLI). We sought to establish the metabolic alterations in irradiated
tumors at early timepoints following treatment.
Materials & Methods
Human HT-29 colon carcinoma cells were inoculated subcutaneously
on both sides of the back of nude mice. Tumors were grown for two
or three weeks. One tumor per animal was treated with 10 or 20Gy
of RT on day 0. The first ten mice were imaged with both FDG-PET
and CT on day -1, 1, 3, 9, and 14. The other 10 mice were imaged
with BLI once a week during tumor growth and on the same days as
the PET-CT study. These findings were correlated with histology.
Results
At the beginning of treatment tumors exhibited low FDG uptake.
The volume of the treated tumors (TT) determined by CT images,
remained stable or decreased (for dose of 20Gy), whereas the un-
treated tumors (UT) continued growing. Surprisingly, 9 days after
RT, the FDG-uptake increased in the TT and remained low in the
UT. We observed a clear decrease in BLI signal in TTs appearing also
9 days after RT.
Conclusion
We have applied preclinical imaging and radiotherapy methods to
study tumor response to treatment. The surprising rise in FDG up-
take at day 9 after RT could be the result of several mechanisms
including inflammation, that still remains to be determined with im-
munohistochemistry. This study raises the possibility of FDG PET
producing false negatives for early response. The preliminary data
reported here will be used to establish future technical and biological
approaches towards monitoring cancer therapies.
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Chapter 1
Introduction
1.1 Purpose
The purpose of this study is to describe the effects of radiation therapy (RT) on
tumor growth and metabolism using different imaging modalities. Performing a
longitudinal study with repeated measurements of a subject over a certain period
of time, allows us to assess the kinetics of tumor response to RT. This can give
a better idea of the time scale of occurring events, as molecular and anatomical
changes as seen by the different imaging tools do not always occur at the same
time. In addition, this study investigates the impact of tumor size and radiation
dose on imaging tumor response. Those factors can influence the outcome of the
tumor, and therefore its reaction to imaging.
1.2 Assessment of tumor response to RT with
molecular imaging
In clinical radiation oncology, the most common way to assess tumor response to
treatment continues to be by examination of changes in the size of the tumor with
anatomical imaging modalities such as computed tomography (CT) or magnetic
resonance imaging (MRI). These anatomical changes in response to therapy, typi-
cally shrinkage of the tumor mass, appear late in the course of treatment, and do
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not reflect the underlying molecular changes occurring much earlier [1, 2]. Under-
standing the early reactions of tumors to radiation therapy (RT) allows for the
fine tuning of the treatment plan in a patient specific manner. If the treatment
does not yield the expected results, an awareness of the negative response early
within the treatment period allows adjustments to be made to the therapy pro-
tocol early on. Tumors exhibit a high degree of biological heterogeneity, and as a
result, patients diagnosed with the same tumor type often do not react similarly
to the same therapy. Detecting molecular level changes in response to RT could
potentially assist with choosing or changing a treatment protocol.
Positron emission tomography (PET) has emerged as a powerful molecular
imaging tool for diagnosis, treatment planning, and monitoring response of mul-
tiple cancer types. It allows the use of a variety of radiotracers to assess different
tumor parameters, the most common being 18F-fluorodeoxyglucose (FDG) which
monitors changes in glucose metabolism. FDG highlights cancer cells, which are
more metabolically active than many non-cancerous cell types, and therefore ex-
hibits higher glucose consumption than the rest of the body. FDG-PET is already
used for monitoring therapy response in multiple cancer types [3, 4, 5]. However
the molecular effects of RT, and their impact on imaging, remain poorly under-
stood. The availability of pre-clinical models for the study of RT is a valuable
tool in understanding the molecular events occurring in response to therapy. Fur-
thermore, non-invasive molecular imaging allows the longitudinal in vivo study
of the same subject over time which provides a great advantage for determin-
ing treatment follow up. PET imaging for the assessment of tumor response to
RT has been evaluated with FDG as well as with other tracers such as 18-F-
fluorodeoxythymidine (FLT), a proliferation marker [6]. Results showed consis-
tent decrease in FLT uptake after RT, but contradictory results for FDG whose
uptake can be either increased [7] or decreased [8] in response to treatment.
Cancer cells within a tumor are not all identical. They also interact with
their environment and modify it. This results in a heterogeneous tumor mass
with different regions harboring different parameters such as variable hypoxia
or aberrant vasculature. These different regions can react in various ways when
treated with radiation [9]. Regions of low oxygen within tumors appear more
resistant to radiation and are therefore important to image. Imaging hypoxia can
2
1.3 Molecular Imaging
be done using PET with different hypoxia tracers such as Cu-ATSM, FMISO,
FAZA or EF5 [10]. Tumor heterogeneities as a result of RT include regions of
pronounced cell death, necrosis or fibrosis formation which can be investigated
with different molecular imaging techniques such as proton magnetic resonance
spectroscopy (MRS) or diffusion weighted (DW) MRI [11], and ultrasound (US)
[12].
An advantage of pre-clinical animal models is the use of reporter genes for
optical imaging using techniques such as bioluminescence imaging (BLI). Cancer
cells expressing luciferase can be monitored non-invasively and allow the assess-
ment of tumor growth or shrinkage in vivo [13, 14].
Altogether, the assessment of tumor response to radiation therapy is complex
as it relies on many parameters such as cancer type, subject, tumor heterogeneity
or tumor microenvironment. Using available tools in molecular imaging, it is
possible to study the effects of radiation on some precise aspects of a tumor.
1.3 Molecular Imaging
“Molecular imaging is the visualization, characterization, and mea-
surement of biological processes at the molecular and cellular levels
in humans and other living systems. To elaborate; molecular imag-
ing typically includes 2- or 3-dimensional imaging as well as quan-
tification over time. The techniques used include radiotracer imag-
ing/nuclear medicine, MR imaging, MR spectroscopy, optical imag-
ing, ultrasound, and others.” D.A. Mankoff [15]
1.3.1 Positron Emission Tomography (PET)
The principle of PET is the administration of positron emitting radionuclide
to a subject. The radioisotope emits a positron, as part of its decay process,
which travels a short distance before annihilation caused by electron interaction.
This process results in the emission of two 511 keV photons going in opposite
directions. The detectors, which are arranged in a circle around the subject,
registers a signal only if two 511 keV photons are detected within an interval of
3
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Figure 1.1: Principle of PET.
approximately 20ns on opposite collinear detectors. It is then possible to retrace
back where the annihilation event had occurred and reconstruct an image (Figure
1.11) [16].
18F-Fluorodeoxyglucose (FDG) PET
FDG is a glucose analog labeled with the radioactive isotope fluorine-18. It acts
as glucose in the body except that after cellular uptake, it gets stuck in the second
step of glycolysis and accumulates in the cell (Figure 1.21). FDG PET therefore
allows monitoring of glucose uptake and metabolism by cells in the body. The
more cells are metabolically active, the more FDG uptake that is observed and
the stronger the signal in PET. This technique can, highlight the regions of high
glucose uptake and consequently tumors which have a high cellular activity [17].
Although it is not strictly tumor specific, FDG PET is a good marker of high
cellular metabolism, which is of importance for several types of cancer, and is the
only PET tracer approved by the FDA for use on a regular basis in the clinic.
1Courtesy of Prof. E. Graves
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Figure 1.2: FDG cell trapping mechanism.
Figure 1.3: Principle of BLI.
1.3.2 Bioluminescence imaging (BLI)
Bioluminescence imaging is a powerful tool that allows the in vivo monitoring of
cells expressing luciferase. Luciferase is an enzyme that reacts with its substrate,
luciferin, and in the presence of oxygen, emits photons (Figure 1.31) that can
be measured using a sensitive charge coupled device (CCD) camera. Luciferin
is not available in mammals, so it has to be injected prior to imaging. BLI is a
useful method, as it can be used to non-invasively monitor luciferase expression
both by constitutively expression to assess live cells, and as a reporter gene for a
chosen specific promoter. For cancer research, cells labeled with luciferase can be
injected in mice to form tumors, whose evolution and growth can be subsequently
followed in vivo with BLI [13].
1.4 Radiation Therapy (RT)
About half of all cancer patients are treated with radiotherapy at some point
during the course of treatment [18]. RT is the treatment of cancer with the
use of ionizing radiation. A beam of electromagnetic radiation (or photons) is
5
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directed to the tumor site with energies ranging from 100 keV to several MeV .
Photons of this level of energy are able to eject electrons from atoms constituting
molecules in a process called ionization. Ejected electrons cause further ionization
when colliding with other molecules. Most of the damage from RT is done by
intracellular ionized molecules which become reactive, as they cause a succession
of chemical reactions that lead to chemical bond breaks. Those breaks occur in
all cellular molecules, including DNA, which is very sensitive to damage due to it
having only two copies and a slow turnover compared to other macromolecules.
DNA damages activate the very efficient DNA repair pathways of cells, but if
the damage is too great, cells die. As tumor cells are prone to having impaired
DNA repair or cell cycle arrest functions, if the DNA is not sufficiently repaired
before division, it can lead to chromosomal aberrations and mitotic catastrophe.
The idea is to induce damages that are fatal to tumor cells while reparable for
normal tissue that will not divide unless DNA is repaired. The dose of radiation
is measured in Gray (Gy) units [19, 20].
“To give an idea of the scale of damage, 1Gy of irradiation will cause
in each cell approximately 105 ionizations, more than 1000 damages
to DNA bases, around 1000 single-strand DNA breaks (SSBs) and
around 20-40 double-strand DNA breaks (DSBs). To put this into
further perspective, 1Gy will kill only about 30 percent of cells for a
typical mammalian cell line, including human.” M.C. Joiner and AJ
Van der Kogel [20]
Usually RT is delivered to a target volume previously determined with treat-
ment planning based on imaging. The dose is delivered from multiple angles to
optimize the dose to the target while sparing normal tissue as much as possible.
The total dose of RT is commonly split into multiple fractions of low dose, pri-
marily to allow normal tissue to recover. Typically, an average clinical RT would
involve 2Gy per day, five days a week, for about 5 weeks [20].
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Multimodality imaging allow the visualization of different aspects of tumor res-
ponse to treatment. FDG-PET-CT and BLI were used in a study for monitoring
chemotherapy (IL-18-Binding protein-Fc therapy) response in lung metastasis
mouse model. All imaging techniques showed an inhibition of tumor progression
when treated with the tested drug [21]. In another study, FDG-PET was used
to analyze the effects of a pre-treatment scan on increasing radiation dose in a
head & neck cancer xenograft mouse model. Results demonstrated that tumors
with higher FDG uptake prior to treatment were more responsive to increasing
RT dose than those with a lower initial FDG uptake [22]. In addition, different
PET tracers were evaluated for monitoring tumor response to RT in pre-clinical
mouse models. This study showed the potential of FMT (O-18F -Fluoromethyl-
D-tyrosine) as an early marker for RT response when compared with FDG or
FLT [7]. Altogether, the studies discussed above create the ground for assessing
tumor response to RT with multimodal imaging.
In this study, a colorectal carcinoma xenograft mouse model was used to assess
tumor response to different doses of RT with FDG-PET-CT and BLI. In this case,
growth and metabolic activity of cancer cells were investigated before and serially
after treatment. Imaging findings were also correlated with histology.
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Materials & Methods
2.1 Cell culture
HT-29 cells (colorectal carcinoma) were thawed and seeded on a large cell cul-
ture dish with 20ml of Mc Coy’s medium with 10% fetal bovine serum (FBS)
and grown in 5% CO2 at 37
◦C in a humidified incubator. Growth media was
changed 3 times per week and cells were trypsinized when they were confluent
(See Appendix A.1 for more details).
Other cells lines were also cultured for previous experiments, and include FaDu
cells (Head & Neck squamous cell carcinoma) and MDA-MB-468 cells (breast
cancer) both expressing luciferase constitutively. Those cells were grown with
Dulbecco’s Minimum Essential Medium (DMEM) with 10% FBS.
2.1.1 Cell transduction
Photinus pyralis (firefly) luciferase under the control of the citomegalovirus (CMV)
promoter retrovirus was kindly provided by the group of Professor AJ Giaccia
(Stanford University, CA, USA). Cells were grown in culture dish, growth medium
was removed, 1.5ml of retrovirus with 2µl polybrene was added to the culture,
and left overnight. The retrovirus were removed the next day and cells were
seeded on a new cell culture dish with growth medium.
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2.2 Tumor model
The tumor model used for these studies was human colon carcinoma mouse
xenograft. HT-29 cells were cultured, and counted using a Neubauer chamber
(See Appendix A.2). One million cells were used for each injection. Nude mice
were anesthetized with 2% isoflurane and 4L/min of oxygen, and cells were in-
jected subcutaneously in the back. Tumors were allowed to grow for 2 to 3 weeks.
Previous experiments using the FaDu and MDA-MB-468 cell lines showed
no tumor formation in vivo (in 4 and 5 mice, respectively), and were therefore
not used further in this study. This can be due to several factors such as a
contamination of cells with mycoplasma, and the presence of the luciferase gene
(which seems unlikely as cells were growing normally in culture), or failed injection
of cells into mice.
2.3 PET-CT Imaging
2.3.1 Outline of experiments
To investigate the differences between anatomical and metabolical changes in
tumors when treated with RT, mice were inoculated with HT-29 human colon
carcinoma cells to form two subcutaneous tumor xenografts per animal. One
tumor per mouse was treated (Treated Tumor: TT), and the other served as
an internal control (Untreated Tumor: UT). Tumor responses were studied for
multiple RT doses and across time. Imaging was performed on day -1 (baseline),
treatment on day 0, and imaging again on day 1, 3, 9 and 14 after RT.
A first study was performed on 15 mice divided into 3 groups of 4 animals
treated with 5, 10 or 20Gy, and 3 unirradiated control mice. The imaging was
performed using a bed holder allowing the simultaneous imaging of 4 mice both
with PET and CT. Due to the occurrence of multiple problems during this ex-
periment, some modifications were made to improve the protocol, and the study
was repeated. These are discussed in section 3.1
A second study investigated the impact of initial tumor size in imaging RT
response. This involved 10 nude mice, 5 of which were inoculated with cells
9
2.3 PET-CT Imaging
2 weeks before RT and the other 5 mice inoculated 3 weeks before RT, which
resulted in small (ranging from 2 to 4mm2) and big tumors (ranging from 6 to
8mm2) respectively. The mice were divided into four groups of two animals each:
small tumors treated with 10Gy, small tumors treated with 20Gy, big tumors
treated with 10Gy and big tumors treated with 20Gy. One untreated big tumor
and one untreated small tumor were used as controls. In this case, mice were
imaged using two different mouse beds for image registration. These comprised
one simple plastic bed and a more complex bed with fiducial markers which were
visible on both CT and PET images. The latter was developed by a colleague,
Geoffrey Nelson (Graves laboratory) and tested here for validation.
2.3.2 FDG-PET
Mice were anesthetized with 2% isoflurane and 4L/min of oxygen in a knock
down box and kept under anesthesia using a nose cone during the radiotracer
injection and imaging. The FDG vial was placed in a lead pig and all manipu-
lations involving the radiotracer were performed behind a lead shield. 200µCi
of FDG was injected intraperitoneally 1 hour before imaging. The remaining
radioactivity in the syringe used for injection was measured to deduce the exact
amount of injected activity. Mice were kept under anesthesia and warmed for 1
hour before imaging. They were then placed on a movable mouse bed, and 10
minute static PET images were acquired on a R4 microPET (Concorde Microsys-
tems, knoxville, TN, USA). These were automatically reconstructed with OSEM
2D.
2.3.3 CT imaging
Once the PET images were acquired, the anesthetized mice were directly trans-
ferred using the mouse bed to the CT scanner (Gamma-Medica Ideas, Northridge,
CA, USA), and a 1 minute scan was performed with the X-ray tube operating at
a current of 225µA and a voltage of 75 kV p. Acquired images were subsequently
reconstructed using filtered back projection with a voxel size of 0.17mm and a
field of view of 110mm.
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2.3.4 Image analysis and quantification
PET and CT images were analyzed using RT Image software 1 [23] using the
procedures described below.
PET-CT image registration
In preliminary studies, imaging was performed with a 4 mice bed. This allowed
higher throughput mouse imaging, but it was difficult to co-register the acquired
PET and CT images. Registering those images has to take into account 6 degrees
of freedom for translation and 6 for rotation, as well as breathing motion and
mouse-specific displacement when moved from the PET to the CT scanner. The
latter effects are difficult to account for, as registration is typically performed by
applying transformations across the entire image. Inaccurate image registration
can lead to imprecise quantification. In the presented results, all mice were imaged
individually, to minimize registration errors.
In the final study, mice were imaged individually. For each mouse and each
timepoint, PET images were overlaid on the CT images, using visual inspection
for the simple bed or a point matching algorithm with fiducial markers. PET
images were normalized with a calibration factor of 1250µCi/ml, and converted
to percent injected dose per gram (%ID/g) using the following equation [24].
%ID/g = (
Activity in a gram of tissue
Injected dose
) ∗ 100 (2.1)
The fused images were then saved in DICOM format for subsequent analysis.
Figure 2.1 shows sample PET-CT images.
Tumor region of interest quantification
Based on the overlaid PET-CT images, tumor region of interests (ROIs) were
manually drawn on coronal view images for multiple slices and subsequently in-
terpolated to encompass the whole tumor volume. Based on these ROIs, datas
such as tumor volume, mean or 90th percentile FDG uptake were computed.
1http://rtimage.sourceforge.net/
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(a) CT, sagital view (b) PET, sagital view (c) PET-CT, sagital view
(d) CT, coronal view (e) PET, coronal view (f) PET-CT, coronal view
Figure 2.1: PET-CT fusion in sagital and coronal views. Red line indicates the
coronal view.
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2.4 Bioluminescence Imaging (BLI)
2.4.1 Outline of experiments
To investigate the kinetics of tumor growth and cell killing after RT, nude mice
were inoculated with HT-29 cells constitutively expressing luciferase. Each mouse
bared two subcutaneous tumors, one treated and one untreated (TT and UT,
respectively).
A pilot study with 5 mice was performed, but the irradiator was out of order
for 5 days at the time the tumors had to be treated. This delay caused the tumors
to become too big for a two weeks follow up period after RT, and therefore had
to be sacrificed before any relevant results were obtained.
This final study involved ten nude mice separated into two groups of four.
Two mice were kept as completely untreated controls. One group received a dose
of 10Gy in one tumor, and the other group received 20Gy. Both tumor growth
and response to RT were monitored as mice were imaged on day 2, 8, 13, 15, 17,
23, and 30 after cell inoculation. Treatment was delivered on day 14.
2.4.2 BLI
Mice were anesthetized with 2% isoflurane and 3L/min of oxygen, then in-
jected intraperitonealy with 2.5µg of luciferin (at concentration 16.7mg/ml), and
placed immediately in the imaging chamber of an IVIS200 (Caliper life sciences,
Alameda, CA, USA), where 5 mice were simultaneously kept under anesthesia us-
ing nose cones. A bioluminescence image was acquired 15 minutes after luciferin
injection, using 30 seconds exposure time, medium binning, and the largest field
of view. The bioluminescence image was then automatically superimposed on a
grayscale photograph, and visualized using a color map.
2.4.3 Image analysis and quantification
Images were analyzed with Living Image 4.0 software. An elliptical ROI was
drawn on each tumor and the average radiance (in p/sec/cm2/sr) as well as the
total flux (in p/sec) was computed.
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Figure 2.2: Representation of RT delivery
2.5 Radiation Therapy (RT)
Mice were anesthetized with an intraperitoneal injection of ketamine-xylazine
solution (8.6% ketamine, 8.6% xylazine in PBS; 10µl per gram of mouse). Ra-
diation delivery was performed using a single field irradiator that consisted of a
treatment table and an RT 250 x-ray tube that was operated 200 kV p with a cur-
rent of 17mA. The dose rate of the system is approximately 30Gy/h. The mice
were positioned under a lead shield (thickness: 1/8 inch or 3.175mm) containing
1 cm apertures where the tumors to be irradiated were placed. For each mouse,
one tumor was irradiated with 10Gy or 20Gy and the other remained untreated
(Figure 2.2).
2.6 Histology
To further investigate the results obtained with in vivo imaging, immunohisto-
chemistry was performed for different relevant markers such as Ki67 for prolifer-
ation, CD-68 for inflammation and CD-34 for vasculature. Only the big tumors
imaged with PET-CT (2 TTs and 2 UTs) were analyzed.
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2.6.1 Tissue sample preparation
When the study was completed, mice were sacrificed with CO2. Tumors were
collected, and fixed in 10% formaldehyde at 4◦C for 24 hours. Tumors were
embedded in paraffin, and sliced at 4µm. Two sections per tumor were stained
with hematoxylin and eosin to assess tissue architecture, and unstained slides
were used for subsequent immunohistochemistry.
2.6.2 Immunohistochemistry (IHC)
Ki67
Tissue samples were stained with Ki67 using the Avidin Biotin peroxidase method,
for both treated and untreated tumors. The first antibody was anti-Ki67, anti-
human made in rabbit (1:250), and was left overnight at 4 ◦C. The secondary
biotinylated antibody was added the next day for 1 hour, goat anti-rabbit (1:200).
The third Avidin/Streptavidin antibody conjugated to HRP was applied for 30
minutes (1:200). Signal was developped with DAB peroxidase. Sections were also
stained with hematoxylin. (See Appendix B for protocols)
CD-68 and CD-34
The immunohistochemistry protocol was similar to the Ki67 described above.
The primary antibodies were anti-CD-68 and anti-CD-34 anti-mouse made in
rat. Multiple variations of the staining protocol were tried, including different
concentration of the primary antibody (1:100, 1:250), two different secondary
antibodies (one made in goat and the other in donkey), and multiple repeats of
the experiment.
2.6.3 Staining quantification
Tissue staining was visualized using a microscope (Leica Microsystems GmbH,
Wetzler, Germany), and typically 3 pictures were taken at different areas within
the sample. The percent of brown staining on each image was calculated, and
averaged to obtain a percent area of staining for each sample section.
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Results
3.1 FDG-PET-CT Imaging
3.1.1 Preliminary studies
An initial study was performed, during which multiple problems were encoun-
tered. The CT scanner was out of order for the baseline scan before RT, and
therefore, no anatomical information was acquired that day. The tumors were
barely visible on the PET images, and the use of a 4 mice bed holder made ROI
determination difficult. This made it difficult to detect potential changes in FDG
uptake. One week after RT, 5 mice (4 treated with 20Gy and 1 untreated, in the
same cage) died. The results from this study were not conclusive, but it provided
the opportunity to make some changes and improve the outcome of the follow-up
experiment. It was decided that RT would be delayed so that the resulting bigger
tumors would be more visible on the PET images. In addition, mice were imaged
individually to allow better image registration.
The results presented here, are from the final study described in Section 2.3.1.
3.1.2 CT Tumor volume
Based on the CT images, it was possible to monitor tumor volume changes during
all the monitored timepoints. We observed that the UT continued their exponen-
tial growth during the time of the experiment as shown by model fitting (Figure
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Figure 3.1: Exponential curve fitting CT tumor volume measurements
3.1). The TT showed a stabilization of tumor size for the group treated with a
dose of 10Gy, and a decrease in tumor size for the groups treated with 20Gy
(Figure 3.2). We could not conclude anything for the small tumors group treated
with 10Gy because the tumor volumes were very small and therefore ROI deter-
mination was too subjective. This difference in tumor volume between treated
and untreated was visible at day 9 only for the small tumors group treated with
20Gy, and appeared later (at day 14) for the other groups (Figure 3.2).
3.1.3 FDG-PET
At the baseline, FDG uptake was low in the HT-29 tumor model (Figure 3.3(a)).
Interestingly, at day 9 after RT, we could observe an increase in FDG consumption
in TTs only (Figure 3.3(d)). In one case, the increased signal remained after 14
days, whereas in others, the signal decreased again at day 14. This result was
confirmed by computing the 90th percentile of tumor FDG uptake. The TT over
UT ratio (TT/UT) reached an average of 1.3 on day 9 after RT (Figure 3.4(a)).
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Figure 3.2: CT tumor volumes. UT volume (darker colors) increases whereas TT
volume (brighter colors) remains stable or decreases.
The increase in FDG uptake was observed for all subjects, but was stronger in
big tumors regardless of the dose received.
3.2 Histology
To further assess why tumor FDG uptake was increased after RT, UTs and TTs
were harvested after the study was completed, embedded in paraffin, sliced and
stained using three different markers. We used an anti-Ki67 antibody, which
stained for proliferating cells and allowed us to see if the increased FDG uptake
could be due to accelerated repopulation after RT. We also labeled CD-34, a
marker of endothelial cells, to assess the vasculature and angiogenesis process,
and CD-68, a macrophage marker, to monitor inflammation.
3.2.1 Tumor size
Tissue sections reflected findings from the CT images in terms of tumor size. We
observed that TTs that received a dose of 20Gy were much smaller than UTs
18
3.2 Histology
(a) Day -1 (b) Day 1 (c) Day 3
(d) Day 9 (e) Day 14
Figure 3.3: Series of PET-CT images of a representative mouse, coronal view.
Tumor FDG uptake is low, but there is an increase in FDG uptake in the TT on
day 9 after RT. A central region not uptaking FDG appears when the UT tumor
reached a certain size on day 9.Green ROI: UT, Red ROI: TT.
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(a) Mean TT/UT
(b) TT/UT for each group
Figure 3.4: TT/UT ratio of tumor 90th percentile of FDG uptake across all
imaging timepoints. There is an increased FDG uptake in the TT at day 9 after
RT.
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(a) TT and UT: 20Gy
(b) TT and UT: 10Gy
Figure 3.5: Picture of representative tumor sections
(Figure 3.5(a)). This difference was not observed in the TTs that received 10Gy
(Figure 3.5(b)).
3.2.2 Hematoxylin and Eosin (tissue architecture)
The hematoxylin and eosin (HE) staining showed heterogeneities within the tu-
mor mass (Figure 3.6). Specifically, we observed a central necrotic region (in
(a)) surrounded by a rim of living cells (in (b)). These findings were supported
by the PET data (Figure 3.3(d)).
3.2.3 Ki67 (proliferation)
Ki67 staining showed that tumor mass was very heterogeneous with an unproli-
ferating central region corresponding to necrotic regions and a rim of proliferating
cells on the edge of the tumor which correspond nicely with the HE staining. The
larger UTs showed more necrosis and therefore less proliferative centers. Figure
3.7 shows Ki67 staining for UT (a) and TT (b) with unproliferating regions in
the center (left), and proliferating regions on the edges (right).
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(a) Necrotic center (b) Rim of cells
(c) Transition region
Figure 3.6: HE staining of a representative tumor
22
3.2 Histology
(a) UT
(b) TT
Figure 3.7: Ki67 staining of a representative UT and TT. Unproliferative (left)
and proliferative (right) regions.
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3.2.4 CD-68 (inflammation) and CD-34 (vasculature)
Unfortunately, neither CD-68 nor CD-34 staining yielded useful results. We ob-
served unspecific staining in the negative control (no primary antibody) which
correlated with the specifically stained regions observed. The staining was lo-
cated mostly in the necrotic areas of the tumors. This unspecific staining was
thought to be due to the secondary antibody that may have recognized regions
of binding within the tissue. A different secondary antibody was also assessed
and showed no unspecific staining, but no specific staining as well. The IHC
experiments were repeated several times, but due to time constraints they could
not be further assessed. The antibodies and protocols for these IHCs thus require
further improvements to enable this type of staining.
3.3 Bioluminescence Imaging
We observed a steady growth of tumors from day 2 on that was similar for both
left and right tumors (Figure 3.8(a), (b), and (c)). Immediately after RT, no
clear difference was observed between TTs and UTs (Figure 3.8(d) and (e)). The
effects of RT began to be visible on day 23 (9 days after RT) where there was a
decrease in BLI signal in TTs (Figure 3.8(f) and (g) left) compared to UTs that
continued their growth (Figure 3.8(f) and (g) right).
Interestingly, UTs on treated mice were smaller and gave a lower BLI signal
than the completely unirradiated control tumors (Figure 3.9). This was explained
by the fact that the lead shield used to protect the rest of the mouse body during
tumor irradiation was not thick enough to block all the radiation. The thickness of
the lead shield was 1/8 inch (3.175mm), and about 10% of the dose went through
the lead, therefore UTs received about 1Gy or 2Gy for the 10Gy or 20Gy group,
respectively. In order to block 99% of radiation, this thickness should be doubled
to 1/4 inch.
Figure 3.10 shows tumor growth and RT response for the different groups
graphically. We observed a stable increase in BLI signal during the first 2 weeks
after inoculation. The BLI signal difference between TTs, UTs, and controls
appeared on day 23 (9 days after treatment) and was further enhanced on day 30
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(a) Day 2 (b) Day 8 (c) Day 13
(d) Day 15 (e) Day 17 (f) Day 23
(g) Day 30
Figure 3.8: BLI of a representative mouse that received a dose of 10Gy to the
left tumor on day 14.
(a) TT and UT (b) Control
Figure 3.9: Comparison between TT, UT and unirradiated control tumors.
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Figure 3.10: Monitoring of tumor growth and response to RT (delivered on day
14) for different doses.
(16 days post RT). The completely unirradiated control tumors showed a steady
increase in BLI signal with the highest signal intensity observed on day 23 and
30 (Figure 3.10, purple line). The UTs that still received 1Gy or 2Gy showed
a higher signal than the TTs but lower than the controls (Figure 3.10, blue and
green lines). The TTs demonstrated a clear decrease in signal after RT, but no
observable difference was noticed between 10Gy and 20Gy, except that the TTs
with 10Gy went up again whereas the 20Gy continued their decrease on day 30
(Figure 3.10, red and yellow lines).
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Discussion
In this study, we imaged a colorectal carcinoma xenograft mouse model before
and after 10 and 20Gy of RT with FDG-PET-CT and BLI. We showed an in-
creased FDG uptake with PET 9 days after treatment, which was probably due
to inflammation. We also demonstrated a stabilization (with 10Gy) or decrease
(with 20Gy) in tumor size with CT, as well as a clear decrease in BLI signal in
treated tumors which was also apparent 9 days after RT.
4.1 TTs volume stabilized or decreased whereas
UTs continued their growth
When tumors were treated with RT, there was a clear difference in tumor size
compared to UT as shown by both CT and BLI. There was a decrease in TT
volume, which was visible on CT images, only in tumors treated with 20Gy,
whereas we only reached a state of tumor control (i.e. volume remained static)
when treated with 10Gy. Those results were detected earlier during the follow
up period (day 9) for the smaller tumors compared with the bigger tumors (day
14). The tumor size was also assessed with histology. It was shown for the big
tumors that TTs treated with a dose of 20Gy were smaller than those treated
with 10Gy. In addition, a clear decrease in TTs BLI signal was visible starting 9
days after treatment and remained 16 days after RT. No difference in BLI signal
was observed when comparing tumors treated with 10 or 20Gy.
27
4.2 Increased FDG uptake after RT
Interestingly, due to a too thin lead shield used during RT, UTs also received
a dose of 1 or 2Gy and showed therefore a smaller size compared to completely
untreated controls. This was visible with BLI, where those tumors showed more
signal than the TTs that got 10 or 20Gy, but a lower signal than the unirradiated
controls. These results were not observed with CT imaging, and showed how
BLI is far more sensitive than anatomical CT imaging in this case for treatment
assessment monitoring.
4.2 Increased FDG uptake after RT
The studied xenograft model showed a very low tumor FDG uptake on the base-
line PET scans before treatment, regardless of tumor size. Surprisingly, an in-
crease in FDG uptake in TTs was observed on day 9 after RT for all TTs, followed
by decrease for some tumors or stabilization for others on day 14. Despite the tu-
mor volumes remaining unchanged in TTs, PET images showed a strong increase
in signal in response to RT.
Different hypotheses to explain this increase were assessed with histology. The
most likely hypothesis was inflammation following RT, but accelerated repopu-
lation and angiogenesis were also considered possible hypotheses. Proliferation
was assessed with Ki67 staining, which highlighted tumor heterogeneities with
an unproliferative center surrounded by a rim of proliferation. These findings
were reflecting the hematoxylin and eosin staining that showed a necrotic center
with viable tumor cells on the edge. However, this was common to both treated
and untreated tumors. We could therefore conclude that the increased FDG up-
take was not due to accelerated repopulation following RT. Unfortunately, the
immunnohistochemistry for inflammation and angiogenesis (CD-68 and CD-34
staining, respectively) did not provide meaningful results. Different antibodies
could be further assessed and the protocol remains to be improved in order to
enable staining for these proteins.
Nevertheless, inflammation seems to be the most likely reason for this increase
in FDG uptake, as described in the literature. Indeed, higher FDG uptake was
observed early on in response to RT [25, 26, 7]. It is known that macrophages and
other activated immune cells within the tumor take up FDG more than normal
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tissue [27]. After RT, immune cells can be recruited to infiltrate the tumor,
therefore increasing the FDG uptake. This phenomenon is well known and has
been exploited to image different inflammatory processes such as atherosclerotic
plaques [28, 29] and infection [30]. FLT, a PET tracer that assesses proliferation,
has been proposed as an alternative to FDG to differentiate tumor cells from
inflammation [31]. Another option is dual time point imaging with FDG, with
early and delayed scans where benign inflammatory processes should give varying
and transient signal compared to more stable signal for malignant lesions [32].
FDG is an unspecific tracer, and hence changes in its uptake level and distri-
bution have to be assessed with caution. Imaging with FDG-PET early on after
RT, or even during treatment if RT is fractionated, can show changes in signal
that do not always correspond to the outcome of the response. Indeed, in a tumor
that is taking up FDG on the baseline scan, any increase in PET signal above
the baseline signal early after RT can be misinterpreted as a radioresistant or un-
responsive tumor. The results of follow up scans therefore have to be interpreted
with the possibility of false negatives from inflammation in mind. Several studies
have reported decreased FDG uptake after treatment both pre-clinically [8] and
clinically [5, 33], this making FDG-PET a good method for assessing response.
In some cases however, FDG-PET may not be the optimal imaging modality to
assess early changes in tumor response to RT.
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Chapter 5
Conclusion
5.1 Research perspectives
This study provided interesting views on the time scale, dose and tumor size
influence of events occurring after RT with respect to imaging. The study had
some limitations, for example the limited number of mice studied in different
groups that made the statistical significance of the results hard to reach.
The cell line used here did not strongly take up FDG, so a similar study
with different cell lines that exhibit a stronger FDG-PET signal would facilitate
the study of early response effects. Also, a subcutaneous tumor model was used,
which is known to be different to tumors growing in their native environment [34].
It would be interesting to repeat a similar study with orthotopic or spontaneously
occurring tumors.
Furthermore, we tested RT delivered as a single fraction, which differs sig-
nificantly from the fractionated regimens that are used clinically, and this could
have led to some differences in molecular response. A fractionated study with
the delivery of multiple low doses of RT would give a better understanding of the
influence of fractionation in imaging tumor response. Another question raised by
those results is the fact that RT was delivered with a single field irradiator with a
lead shield to protect the mouse body from radiation which was not thick enough
to block all the dose. It would be worth repeating the experiments with a thicker
shield to make sure that the untreated tumor does not receive any significant
dose.
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In addition, the use of a conformal microCT (able to deliver radiation from
multiple angles), would be interesting in that we would get a result closer to
the clinical situation [35]. Thus far, the dose rate achieved with this system is
lower than the single field irradiator which would not only mean that big studies
involving many mice would be very time consuming, but also that the radiobiology
of molecular effects would be different.
Finally, investigating tumor response to RT with other imaging modalities
would bring supplementary important molecular aspects in the picture. An ex-
ample would be the use of a fluorescent peptide that binds to integrins [36] to
study the effects of RT on tumor vasculature and angiogenesis. We could also
consider imaging with different PET tracers that would allow the understanding
mechanisms such as proliferation with FLT, or hypoxia with EF5.
5.2 Conclusion
Imaging and radiation oncology are closely interconnected, especially at the treat-
ment planning level. Assessment of tumor response to RT is a growing and active
field of research, which aims at a better and more patient specific treatment of
cancer. Identifying and understanding the early molecular events occurring after
RT would allow improved interpretation of images. Indeed, being able to detect
false negatives (i.e. differentiate between events such as inflammation and ra-
dioresistance) early on with non-invasive imaging would allow for an adaptation
of the treatment protocol, which could directly benefit the patients.
This study provided an insight of the complexity of imaging tumor response to
radiotherapy and highlighted the research efforts that still remain to be performed
in this field.
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Appendix A
Cell culture
A.1 Cell medium change & Splitting
The growth medium for the cells was Mc Coy’s Medium with 10% fetal bovine
serum (FBS) in 5% CO2 at 37
◦C in a humidified incubator. Cell culture manip-
ulations were performed under a fume hood.
Cells were thawed and seeded on a 10cm cell culture dish with 20ml of growth
media and kept in an incubator.
Growth media was changed three times a week by removing the media and
adding 20ml of fresh media in the cell culture dish .
When the dish was confluent, about once a week, cells were split in two dishes.
The culture media was removed and cells were rinsed with 5ml of PBS. Then 5ml
trypsin was added, and left for a few minutes in the incubator until cells were
well detached. Cells were mixed by pipetting up and down, and the desired
quantity was then seeded on a new dish, with fresh growth media, and kept in
the incubator.
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A.2 Cell counting
Cell counting was performed every time the amount of cells needed to be assessed
for further experiments. Growth media was removed and cells were rinsed with
5ml PBS. 5ml of trypsin was added and cells were left in incubator for 5 minutes
until cells were detached. Detached cells together with trypsin were mixed by
pipetting up and down and added to 25ml of growth media in a tube so the
total volume was 30ml. In a small well, 40 µl of trypan blue (stain used for the
visualization of alive cells) and 10µl of cells from tube were added and mixed.
10µl of which were introduced in a Neubauer chamber. Under the microscope,
cells present in squares of the Neubauer chamber were counted. The number of
cells per ml can then be deduced by using the following formula:
c · v · d · 1000
s
where c is the number of counted cells, v is the volume in the chamber (here
10µl), d is the dilution (here 5), 1000 is to convert to ml, and s is the number of
squares (here 9).
Knowing the concentration of cells, it was then possible to centrifuge and
resuspend the cells in an appropriate volume of culture media for further use.
A.3 Cell freezing
In order to keep cells for further purposes, some cells were frozen. Cells were
counted, centrifuged at 1300 rpm at room temperature for 5 minutes, and re-
suspended in an appropriate volume of Fetal Bovine serum (FBS) with 10% of
DMSO (cryo protective agent). Cells were subsequently stored in a cryo freezing
container at -80◦C.
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Appendix B
Immunohistochemistry
B.1 Ki67 staining Procedure Avidin Biotin (Per-
oxidase method)
Everything at Room Temp unless otherwise specified
1. Dewax with xylene about 10-15 minutes.
2. Rehydrated
Absolut EtOH 5 min
95◦C EtOh 5 min
85◦C EtOH 5min
70◦C EtOH 5min
H2Od 5 min
3. Antigen retrieval with 10mM Citric Acid pH=6. 2-3 minutes in a microwave
(repeat 3 or 4 times). Cool till RT (around 20 minutes)
4. Rinse in 1x PBS 3 x 5min.
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5. Peroxidase quenching with 3% H2O2 (4.3ml of 35% H2O2 in 50 ml of PBS
1X) for 10 minutes
6. Rinse in tap water
7. Humid Chamber (Tip box)
8. Wash 3 times with PBS 1X
9. Avidin Biotin quenching using Avidin D Biotin (solution) for 5 minutes.
10. Rinse in PBS
11. Block with Biotin blocking reagent at RT
12. Rinse in PBS
13. Apply 10% blocking serum (goat) 0.1% Tween/ PBS mixture for 1h. PBS-
Tween 0.1%-Serum10%
14. Apply Primary Antibody/ Blocking Serum (same as above) mixture (1:250)
in Cold Room (4◦C). Leave Overnight; PBS-Tween 0.1%-%-Ab
15. Rinse in 1x PBS 3 x 5min (or PBS-Tween 0.1% and last with PBS). For
the last PBS I preferable to wash out the soap
16. Apply Secondary biotinylated Antibody / Blocking Serum (same as above)
mixture (1:200) for 1 hr. PBS-Tween 0.1%-Serum1%-Ab 2nd. Biotin-
Avidin/Streptavidin system amplifies the signal as each Biotin molecule
binds 6 Avidin/Streptavidin molecules.
17. Rinse in 1x PBS 3 x 5min in cup (or PBS-Tween 0.1% and last with PBS)
18. Dilute the third Avidin/Stretavidin antibody conjugated to HRP or fluo-
rochrome in blocking solution (1:200) and incubate at room temperature
for 30-45 minutes
19. Wash 3 times for 5 minutes with PBS 1X
35
B.1 Ki67 staining Procedure Avidin Biotin (Peroxidase method)
20. Develop signal (Vector Laboratories DAB substrate Kit for Peroxidase).
Bring the solution to RT and add one drop of DAB to 1 ml of substrate.
Mix well. Apply this solution at RT and monitor signal development as
soon as some signal is seen
21. Wash sections for 5 minutes in distilled water.
22. Immerse very quickly in Haematoxylin
23. Rinse in water
24. Mount with Fluoromount-G with anti-fading agents
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